Myovant Sciences Inc

Alexza Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The company's technology, the Staccato system, vaporizes unformulated drug compound to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. Alexza Pharmaceuticals has four product candidates in clinical development: AZ-001 (Staccato prochlorperazine) for the treatment of acute migraine headaches; AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder; AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia; and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain. Alexza Pharmaceuticals is located in Palo Alto, Calif.

Portola Pharmaceuticals is a Bay Area–based pharmaceuticals company with a focus on bioresearch and drug development. Their efforts are directed towards global markets, specifically in the treatment of cardiovascular disease and inflammation. Generated from their available business information

Aimmune Therapeutics is a biopharmaceutical company based in Brisbane, CA, that is dedicated to developing innovative medicines for the treatment, prevention, and management of food, gastrointestinal (GI), and metabolic-related diseases. As a Nestlé Health Science company, Aimmune aims to be a global leader in this field, providing standardized, science-driven treatments for patients and their families who have limited or no other options. With a focus on reducing the burden of serious and potentially life-threatening conditions, Aimmune pushes the boundaries of medicine to enable individuals to live life on their own terms. By uniting the best minds in clinical research and biotechnology, the company is actively working on its pipeline of therapies to address these diseases and improve the lives of patients and caregivers.Generated from the website